Advertisement
Advertisement
U.S. markets close in 4 hours 32 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Edesa Biotech, Inc. (EDSA)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.9051+0.0051 (+0.57%)
As of 11:16AM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Shooting Star

Shooting Star

Previous Close0.9000
Open0.9000
Bid0.9001 x 1100
Ask0.9100 x 2200
Day's Range0.8822 - 0.9200
52 Week Range0.7600 - 6.7200
Volume18,392
Avg. Volume194,850
Market Cap17.517M
Beta (5Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-1.1250
Earnings DateDec 28, 2022 - Jan 02, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for EDSA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Edesa Biotech, Inc.
    Daily – Vickers Top Insider Picks for 06/13/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    6 months agoArgus Research
View more
  • ACCESSWIRE

    Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market

    Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the closing a private placement directly with investors priced at-the-market under the rules of the Nasdaq Stock Market of 2,691,337 common shares, 12-month warrants to purchase up to an aggregate of 1,345,665 common shares and 3-year warrants to purchase up to an aggregate of

  • Zacks Small Cap Research

    EDSA: Statistically Significant Mortality Reduction in Phase 2 ARDS Trial…

    By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Statistically Significant Mortality Reduction in Phase 2 ARDS Trial On September 30, 2022, Edesa Biotech, Inc. (NASDAQ:EDSA) announced final results from the Phase 2 portion of its ongoing Phase 2/3 clinical trial evaluating EB05, the company’s monoclonal antibody therapy that targets toll-like receptor 4 (TLR4),

  • ACCESSWIRE

    Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study

    Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced final results from the Phase 2 portion of its ongoing Phase 2/Phase 3 clinical study. study is evaluating the company's monoclonal antibody candidate, EB05, as a single-dose treatment for hospitalized patients with or at risk of developing Covid-19 induced Acute Respiratory Distress Syndrome (ARDS).

Advertisement
Advertisement